Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Growing from a small community led initiative to a major fundraiser, the The Walk of Champions began with a modest $12,000 ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.